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Abstract: (1) Background: High iron associates with inflammation and type 1 diabetes (T1D). Iron is
essential not only for neonatal development but also for infectious microorganisms. The neonatal
immune system is immature, and innate immunity prevails before immunocompetence develops.
(2) Methods: In 398 newborns from the Danish Newborn Screening Biobank, we examined if whole
blood iron (WB-Iron) content were associated with cytokines, adipokines, C-reactive protein (CRP),
and mannose-binding lectin (MBL) in non-infected healthy neonates, and if these associations differed
in newborns who later developed T1D (cases) (n = 199). WB-Iron was quantified using laser ablation
inductively coupled plasma mass spectrometry on the neonatal dried blood spots. For each analyte,
the relative change (RC) in the mean level was modeled by robust log-normal regression. (3) Results:
A one unit increase in neonatal WB-Iron was associated with a 38% decrease in mean interleukin
(IL)-6 levels (0.62; 95% CI: 0.40–0.95, p = 0.03), and a 37% decrease in mean MBL levels (0.63;
95% CI: 0.41–0.95, p = 0.03), but was not statistically significant after correction for multiple testing.
(4) Conclusions: In summary, we found that higher neonatal WB-iron content was inversely associated
with IL-6 and MBL, which may increase susceptibility to infections.
Keywords: cytokines; adipokines; diabetes mellitus; type 1; iron; TREM1; human; C-reactive protein;
mannose-binding lectin; infant; newborn
1. Introduction
The neonatal immune system is immature, and innate immunity prevails before
immunocompetence develops. Following birth and during early childhood, the immune system
must rapidly develop to adapt to the infectious microorganisms in the extrauterine environment as
well as to establish tolerance to abundant non-pathogenic antigens [1]. The innate immune system
is important, especially during early life, and represents the first line of defense against pathogenic
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microbes [2]. As part of the innate immune system, mannose-binding lectin (MBL) binds to pathogens
and activates the complement pathway [3]. Cytokines, which act as intercellular signaling molecules
in the immune system, regulate not only the innate immune system (e.g., tumor necrosis factor alpha
(TNFα), interleukin (IL)-1β, IL-6, IL-8, IL-10, IL-12) but also the adaptive system (IL-4, interferon
gamma (IFNγ), and transforming growth factor beta 1 (active form) (TGFβ)).
Iron (Fe) is an essential trace element not only for neonatal development but also for infectious
microorganisms. Sequestration of circulating iron prevents bacterial iron utilization [4]. This mechanism
is regulated by hepcidin, which is increased in response to infection and inflammation and induced by
IL-6, a pattern belonging to the innate immune system. Defects in hepcidin production are associated
with iron overload disorder hemochromatosis (hepcidin deficiency), anemia of chronic inflammation
or anemia of iron deficiency (hepcidin excess) [5,6]. Sequestration of iron also occurs independently of
hepcidin, in response to TNFα, IL-1β, and IFNγ [7]. In adults, iron overload is associated with increases in
complement C3 and C-reactive protein (CRP), an acute phase reactant in inflammation and infection and
regulated by IL-6 [8]. The hypothesis of a bidirectional cross-talk between iron and the immune system has
emerged recently, but this interaction is still poorly understood [9,10]. Results from each end of the iron
status spectrum, for example, severe deficiency (iron-deficiency anemia) and extreme overload (hereditary
hemochromatosis (HH) and beta-thalassemia major), have indicated changes in lymphocyte proliferation
and cytokine profiles [9,10].
Iron overload is associated with diabetes in adults and children [11–13]. The mechanism involved
is most likely due to intracellular iron accumulation in beta cells, generation of oxidative stress,
and apoptosis [14,15]. However, increased iron is also associated with type 2 diabetes [12], which is
characterized by insulin resistance combined with beta-cell failure, and adipokines (e.g., adiponectin,
leptin) function as intercellular molecules between adipose tissue and pancreas [16].
Till date, no studies have examined if a link between physiological levels of circulating iron
measures and a variety of cytokines, adipokines or immune response proteins exist in a non-infected
healthy neonatal population, which could provide new insights regarding the role of iron in
immunological health and disease. Manipulation of iron status may potentially represent a simple
way of (re)-gaining immunological homeostasis [17].
Utilizing neonatal dried blood spots (NDBS) from the unique Danish Newborn Screening
Biobank (DNSB) [18], we aimed to elucidate if: i. neonatal whole blood iron (WB-Iron) content
was associated with cytokines, adipokines, and other proteins involved in the immune response (CRP,
MBL, and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1)) and ii. case status
(neonates that later develops childhood type 1 diabetes (T1D) versus neonates that do not develop
childhood T1D) was an effect modifier of the latter associations.
2. Materials and Methods
2.1. Overview of Study Design and Sampling
This population-based study consists of a case-cohort sample from the DNSB [18], which is located
at Statens Serum Institute, Copenhagen, Denmark. Since 1981, the dried blood spots (DBS) have been
stored at −20 ◦C/−4 ◦F in the DNSB, and this biobank covers close to 100% of the Danish population
born since 1982 [19].
Originally, the sample consisted of triplets (1:2) [20], but only duplets (1:1) had whole blood
iron content measured [11], which restricts this study to a 1:1 sampling. Cases and controls were
matched on date-of-birth. Participants were born between January 1991 and November 1998 and
cases developed T1D before the age of 16 years (detailed information about the study sample is given
elsewhere [11,20]). Briefly, T1D diagnosis was classified according to World Health Organization
International Classification of Diseases (ICD) criteria using ICD-8 (codes: 249 and 250) and ICD-10
(codes: DE10.x–14.x) (ICD-9 has not been used in Denmark). Cases have been thoroughly validated by
the Danish Registry of Childhood and Adolescent Diabetes (DanDiabKids) [21].
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We had complete exposure and outcome data on 398 participants (199 cases and 199 controls) (see
a flow chart of participants in Figure 1).
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2.2. Exposure Assessment
2.2.1. Assessment of Whole Blood Iron Content
The samples were analyzed for iron (56Fe) using laser ablation inductively coupled plasma mass
spectrometry (LA-ICP-MS). The samples w re also analyzed f r potassium (39K) in the ame run
to control for blood volume on the NDBS and the hematocrit value in the newborn [22]. All of the
samples were analyzed together to minimize operation l variation [11,23].
The LA-ICP-MS measures 12 consecutive points on each NDBS, which increases the accuracy of
the neonatal WB-Iron content (total sum/12) [24,25]. Further, LA-ICP-MS measur s the ion intensit in
cou ts per second, which is proportional to the iron concentration. The unit of m asurement is total
iron io content in capillary whole blood rel tive to the total potassium ion content in capillary whole
blood [11].
During the study period (1991–1998), the same filter paper had been used, thereby eliminating
the risk of including filter paper with different iron-binding capacity.
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2.2.2. Other Variables
A number of basic variables and possible confounders were available. These variables and their
coding are presented in Table 1.
Table 1. Characteristics of the study sample (including specification of missing values).
Variables Cases(n = 199)
Controls
(n = 199)
Sex 1
Female, n/% of total 103/51.8 95/47.7
Gestational age 2,
Median/interquartile range (IQR), weeks 40.0/1.0 40.0/2.0
Birth weight 3,
Median/IQR, grams 3500/630 3500/744
Maternal age 4,
Median/IQR, years 29.0/6.0 28.0/8.0
Season of blood sampling, n/% from total
Winter
Spring
Summer
Autumn
41/20.6
49/24.6
59/29.6
50/25.1
40/20.1
49/24.6
60/30.2
50/25.1
Period of blood sampling, n/% from total
1991–1993
1994–1998
109/54.8
90/45.2
109/54.8
90/45.2
Human leukocyte antigen (HLA)-risk groups 5, n/% from total
High/moderate 6
Low/protective 7
151/82.5
32/17.5
68/40.0
102/60.0
Missing values: 1 11 controls, 2 1 case and 16 controls, 3 1 case and 17 controls, 4 11 controls, and 5 16 cases and
29 controls. HLA-DQB1 genotype (allele_1/allele_2): 6 03:02/99:99, 03:02/02, 06:04/03:02, 03:01/02, 06:03/03:02,
02/99:99, 06:04/02, 06:04/99:99, 03:01/03:02. 06:04/03:04, and 7 06:02/03:02, 06:02/99:99, 06:02/02, 06:03/99:99,
03:01/99:99, 06:02/03:01, 06:03/03:01, 06:04/03:01, 06:03/02, 03:04/99:99, 03:04/02, 06:02/03:04, 99:99/99:99. NB:
99:99 = remaining alleles.
2.3. Outcome Assessment
Fourteen analytes were quantified on the 3.2 mm diameter NDBS using a multiplexed sandwich
immunoassay, based on flowmetric Luminex xMAP® technology. These were: i. cytokines: IL-1β,
IL-4, IL-6, IL-8, IL-10, IL-12(p70), IFNγ, TNFα, TGFβ; ii. energy hormones/adipokines: leptin and
adiponectin; and iii. CRP and MBL involved in innate immunity, and sTREM-1 belonging to the
immunoglobin superfamily. Biomarker analyses are described in depth elsewhere [26]. In all assays,
matched pairs were analyzed together to avoid operational variation [23].
Quality control of the analysis was made using mouse IL-6 as an internal analyte added to
the extraction buffer to detect pipetting errors, and biotinylated beads to detect signal errors [27].
Calibration curves were used on each plate together with one high and two low controls.
Samples, calibrators, and controls were analyzed in duplicates.
2.4. Statistical Analysis
For each analyte, the relative change (RC) in the mean level by one unit increase in neonatal
WB-Iron content was modeled by a robust log-normal model regression, which takes into account:
i. that measurements are potentially both left and right censored; and ii. correlation within
immunoassay. To account for correlation within immunoassay, an inference was based on a working
independence generalized estimation equation (GEE) approach.
The simultaneous evaluation of neonatal WB-Iron content on all analytes was done using the
model stacking approach detailed in Pipper et al. [28]. Subsequent adjustment for multiple testing
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and familywise 95% confidence bands (95% CI) were calculated using the single step procedure by
Hothorn et al. [29]. GEE estimates of mean ratios and accompanying confidence limits were calculated
on a log-scale and transformed back to the original scale.
Model selection was done prior to statistical analyses based on our previous work using these
data: i. univariate models; and ii. primary adjusted models using possible confounders (covariates
associated with neonatal WB-Iron content (sex, case status, and maternal age) (see Kyvsgaard et
al. [11]).
Overall functional misspecification by including neonatal WB-Iron content as a trend (linear
variable) was assessed by a lack-of-fit test. Specifically, we included a quadratic term of neonatal
WB-Iron content and tested its significance by a robust Wald test.
Due to the fact that our study population consisted of neonates who later developed childhood
T1D (n = 199) and those who did not develop T1D (n = 199), we also performed adjusted stratified
analyses to examine if the relationship between analytes and WB-Iron content may be different
between cases and controls. Further, if estimates differed between cases and controls, we examined
this difference using the test of interaction (p-difference) [30].
We also performed post-hoc analyses to secure that the associations between neonatal WB-Iron
content and IL-6 and leptin were independent of leptin and IL-6 levels, respectively. This was done
due to previously described positive associations [31,32]. Due to the observed positive and u-shaped
associations between these two analytes, in the present study, the adjustments were done using proper
linear and non-linear (quadratic term) modeling (Figure S1).
P-values were evaluated at a two-sided 5% significance level, and prior to our statistical analyses,
we decided to include both the results with and without adjustment for multiple testing.
All analyses were made using the statistical software package R version 3.5.1 (the R foundation
for statistical programming, Vienna, Austria), the add-on packages survival, and multcomp.
2.5. Ethics
The study was performed in accordance with the Helsinki II Declaration. Furthermore, the study
was approved by the Danish Ethical Committee (H-2-2014-007) and by the DNSB Steering Committee.
According to Danish law, anonymous studies do not require further informed consent.
3. Results
3.1. Basic Characteristics
Characteristics of the study population are presented in Table 1.
Overall median (Q1, Q3) WB-Iron content was 1.75 (1.56, 1.95) units. When stratifying by case
status, the median WB-Iron contents were 1.76 (1.59, 1.98) and 1.74 (1.54, 1.94) units for cases and
controls, respectively. Median (Q1, Q3) concentrations, by case status, for the 14 analytes are presented
in Table S1. Spearman’s correlation between the cytokines, adipokines, and other proteins involved in
the immune response are depicted in Figure S2.
3.2. Unadjusted Models
For one unit increase in neonatal WB-Iron content, there was a 38% decrease in mean IL-6 levels
(0.62; 95% CI: 0.40–0.95, p = 0.03) and a 38% decrease in mean MBL levels (0.62; 95% CI: 0.41–0.95, p =
0.03) (Table 2). These associations did not remain statistically significant after correction for multiple
testing (Table 3).
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Table 2. Relative change in mean levels of cytokines, adipokines, and other proteins involved in
the immune response with 95% confidence bands by 1 unit increase in neonatal whole blood iron
content—results from models without correction for multiple testing.
Outcome Variable Univariate Model p-value Multivariate Model p-value
IL-1β WB-Iron content 1.42 (0.97; 2.07) 0.07 1.37 (0.93; 2.03) 0.11
IL-4 WB-Iron content 1.03 (0.82; 1.30) 0.78 1.05 (0.83; 1.33) 0.69
IL-6 WB-Iron content 0.62 (0.40; 0.95) 0.03 0.62 (0.40; 0.95) 0.03
IL-8 WB-Iron content 1.09 (0.89; 1.32) 0.41 1.13 (0.92; 1.39) 0.25
IL-10 WB-Iron content 0.78 (0.43; 1.42) 0.41 0.69 (0.37; 1.27) 0.23
IL-12 WB-Iron content 1.25 (0.90; 1.75) 0.19 1.25 (0.90; 1.75) 0.18
IFNγ WB-Iron content 1.10 (0.84; 1.45) 0.47 1.09 (0.83; 1.44) 0.53
TNFα WB-Iron content 0.94 (0.67; 1.32) 0.70 0.99 (0.70; 1.40) 0.95
TGFβ WB-Iron content 0.92 (0.72; 1.18) 0.52 0.96 (0.76; 1.21) 0.73
Adiponectin WB-Iron content 1.09 (0.89; 1.34) 0.39 1.12 (0.91; 1.37) 0.28
Leptin WB-Iron content 0.79 (0.59; 1.05) 0.11 0.85 (0.65; 1.12) 0.26
CRP WB-Iron content 0.81 (0.56; 1.17) 0.26 0.76 (0.52; 1.12) 0.17
MBL WB-Iron content 0.62 (0.41; 0.95) 0.03 0.63 (0.41; 0.95) 0.03
sTREM-1 WB-Iron content 0.97 (0.69; 1.37) 0.88 0.98 (0.69; 1.39) 0.90
Bold letters indicate significance at a two-sided 5% level. Covariates included in the multivariate models are:
neonatal whole blood iron (WB-iron) content, sex, maternal age, and case status (childhood type 1 diabetes
(yes/no)). IL, interleukin; IFNγ, interferon gamma; TNFα, tumor necrosis factor alpha; TGFβ, transforming growth
factor beta; CRP, C-reactive protein; MBL, mannose-binding lectin; sTREM-1, soluble triggering receptor expressed
on myeloid cells-1.
Table 3. Relative change in mean levels of cytokines, adipokines, and other proteins involved in
the immune response with 95% confidence bands by 1 unit increase in neonatal whole blood iron
content—results from models with correction for multiple testing.
Outcome Variable Univariate Model p-value Multivariate Model p-value
IL-1β WB-Iron content 1.42 (0.81; 2.48) 0.59 1.37 (0.77; 2.44) 0.74
IL-4 WB-Iron content 1.03 (0.74; 1.45) 1.00 1.05 (0.74; 1.49) 1.00
IL-6 WB-Iron content 0.62 (0.33; 1.16) 0.28 0.62 (0.33; 1.16) 0.29
IL-8 WB-Iron content 1.09 (0.81; 1.45) 1.00 1.13 (0.83; 1.53) 0.97
IL-10 WB-Iron content 0.78 (0.32; 1.89) 1.00 0.69 (0.28; 1.70) 0.95
IL-12 WB-Iron content 1.25 (0.77; 2.04) 0.91 1.25 (0.77; 2.04) 0.90
IFNγ WB-Iron content 1.10 (0.74; 1.65) 1.00 1.09 (0.73; 1.64) 1.00
TNFα WB-Iron content 0.94 (0.57; 1.55) 1.00 0.99 (0.59; 1.64) 1.00
TGFβ WB-Iron content 0.92 (0.64; 1.32) 1.00 0.96 (0.68; 1.36) 1.00
Adiponectin WB-Iron content 1.09 (0.81; 1.48) 1.00 1.12 (0.83; 1.51) 0.98
Leptin WB-Iron content 0.79 (0.51; 1.21) 0.73 0.85 (0.57; 1.28) 0.97
CRP WB-Iron content 0.81 (0.47; 1.40) 0.97 0.76 (0.43; 1.35) 0.89
MBL WB-Iron content 0.62 (0.33; 1.15) 0.28 0.63 (0.34; 1.16) 0.29
sTREM-1 WB-Iron content 0.97 (0.59; 1.61) 1.00 0.98 (0.58; 1.65) 1.00
Covariates included in the multivariate models are: neonatal whole blood iron (WB-iron) content, sex, maternal
age, and case status (childhood type 1 diabetes (yes/no)). IL, interleukin; IFNγ, interferon gamma; TNFα, tumor
necrosis factor alpha; TGFβ, transforming growth factor beta; CRP, C-reactive protein; MBL, mannose-binding
lectin; sTREM-1, soluble triggering receptor expressed on myeloid cells-1.
3.3. Adjusted Models
For one unit increase in neonatal WB-Iron content, a 38% decrease in mean IL-6 levels (0.62; 95%
CI: 0.40–0.95, p = 0.03) and a 37% decrease in mean MBL levels (0.63; 95% CI: 0.41–0.95, p = 0.03)
were found (Table 2). However, these associations were not statistically significant after correction for
multiple testing (Table 3). In addition, we found no sign of non-linear associations.
3.4. Sensitivity Analyses
When stratifying on case status and performing the adjusted models, we found the same directions
of effect regarding MBL and IL-6, but naturally with a reduction in power. In cases, leptin was inversely
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associated with neonatal WB-Iron content (0.58; 95% CI: 0.36–0.92, p = 0.02) compared to (1.09; 95% CI:
0.78–1.51, p = 0.63) in controls (p-difference = 0.03). Furthermore, IL-1β was positively associated with
neonatal WB-Iron content (2.01; 95% CI: 1.10–3.67, p = 0.02) but not in controls (1.14; 95% CI: 0.64–2.03,
p = 0.67) (p-difference = 0.24). When corrected for multiple testing, the results were not significant
(Table S2).
Our post-hoc analyses showed that the association between WB-iron and IL-6 was unaltered
when leptin was included in the unadjusted model (independent effect) and vice versa.
4. Discussion
In this study, we investigated the association between neonatal WB-Iron content and cytokines,
adipokines, and other proteins involved in the immune response, and if this was different in neonates
who later developed childhood T1D vs. those who did not. No previous study has investigated this
association in neonates. Overall in adjusted models, we found inverse associations between WB-Iron
content and circulating neonatal IL-6 and MBL. In newborns, who later developed T1D, we found an
inverse association between WB-Iron levels and leptin, which was different from that in controls, and a
positive association with IL-1β, which was not different from that in controls. Adjustment for multiple
testing removed these associations.
4.1. Comparison with Other Studies
The finding of an inverse association between neonatal WB-Iron content and circulating neonatal
IL-6 levels is in line with murine studies that the peptide hormone hepcidin, which is up-regulated
in response to higher iron levels, suppresses IL-6 gene expression upon inflammatory stimuli [33].
Newborns are at risk of severe infections, and this is due in large part to a naïve adaptive immune
response [34]. Iron is needed for bacterial growth, and too much circulating neonatal iron may pose a
risk in regards to providing a favorable milieu for bacterial growth [35]. Thus, these results may point
to a modulatory effect of physiological high iron levels on IL-6 production possibly mediated through
hepcidin. Though other murine studies have found that in vitro macrophage cytokine production,
for example, IL-6 and TNFα, is caused by low intracellular iron levels [36].
Iron deficiency in acutely ill hospitalized children (n = 142, mean age = 3 years), in Malawi,
has been linked with increased IL-6 production from lymphocytes examined ex vivo [37]. In contrast,
a study in healthy Indonesian infants (n = 52, age range = 3–9 months) found no association between
iron deficiency and ex vivo whole blood cytokine production, including IL-6 production [38], though
this study was underpowered.
IL-6 has been positively associated with an increased transferrin receptor density on hepatocytes
favoring iron storage in the liver, an increase in ferritin synthesis, and a decrease in transferrin receptor
synthesis [37]. In our study, higher neonatal WB-Iron content seems to decrease circulating IL-6, which
in the light of the formerly mentioned effects of IL-6 on iron homeostasis makes sense regarding no
need for further intracellular iron storage/accumulation, but at the expense of providing a substrate
for microbial agent growth.
We also found an inverse association between neonatal WB-Iron content and circulating neonatal
MBL levels. MBL is a protein of innate immunity, an acute phase protein, that activates the complement
system and promotes phagocytosis [3]. Lower MBL levels in the neonatal period and up through
childhood have been associated with higher risk and progression of severe infections [3], and higher
MBL levels are found in children with newly diagnosed childhood T1D [39]. To our knowledge,
no studies have examined the association between iron and MBL levels in a pediatric population,
but a small study designed to examine the safety of five different intravenous iron preparations
found no association between supra-physiological iron loading and MBL concentrations in adults [40].
In addition, it is important to mention that serum polymerization is critical for the biological activity
of MBL, which we, unfortunately, have not been able to account for [3].
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We also found an inverse relationship between neonatal WB-Iron content and circulating neonatal
leptin levels, which seems only to be present in the case group. Leptin is a major regulator of appetite,
energy homeostasis, metabolism, and may also influence the immune response, for example, a decrease
in leptin levels is associated with an increase in infection susceptibility [31,41]. Our finding has also
been demonstrated among in vitro, murine, and human studies [42]. The molecular mechanism
behind this inverse association seems to be through regulation of leptin transcription by iron in the
adipocytes [42]. Our research group has previously found a 26% reduction in leptin levels in newly
diagnosed patients with childhood T1D compared to their siblings without childhood T1D [41] but
have not been able to find differences in leptin levels between neonates that later develops childhood
T1D and their controls [20]. Whether the inconsistency in the two latter study results is due to
different/same iron distributions between groups and/or time-dependent effects remains unexamined.
Noteworthy, leptin may also mediate the production of other cytokines, for example, IL-6, which
adds an extra layer of complexity in deciphering which cytokine-pathways are iron-sensitive and
which are influenced by other cytokines/immune mediators [31], but we found that the associations
between neonatal WB-Iron content and IL-6 and leptin were unaltered after adjusting for leptin and
IL-6 levels, respectively.
Despite that iron overload is associated with increases in complement C3 and CRP in adults [8],
we did not find associations between WB-Iron and CRP in neonates. This is most likely explained by
either: i. WB-Iron content was not being sufficiently high, or ii. the duration of exposure had not been
long enough to induce chronic inflammation in the neonate.
Most cells in both the innate and adaptive immune system can express IL-10 [43]. IL-10 suppresses
inflammation by suppressing various cytokines, including IL-1β and TNFα [44], which is also a
mechanism involved in down-regulating hepcidin expression and alleviation of anemia [45]. On the
other hand, in sickle cell anemia, iron overload suppresses IL-10, which may contribute to the
production of free radicals [46]. However, we observed that WB-iron was negatively correlated
with IL-10 levels in all analyses, but not statistically significant, which could be explained by newborns
having an impaired IL-10 production compared to adults [47].
4.2. Strengths and Limitations
The strengths of the study include a large number of cytokines, adipokines, and other proteins
involved in the immune response measured in a large number of newborns (n = 398). No previous study
has examined the link between early life physiological iron status and the immune system in healthy
non-infected neonates. As the study was performed in newborns, extrauterine environmental exposure
was unlikely to confound the results, but we cannot rule out any maternal dietary, immunological,
or nutritional influences on the newborn. The iron status of the newborn is most likely influenced
by the mother’s nutritional iron status, but also maternal and fetal/newborn iron metabolism
genetic make-up [48]. Our results could be confounded by other unexamined but associated
micro-nutritional factors. Although the newborns were healthy at the time of blood sampling, 50%
later developed childhood T1D, which may attenuate the generalizability of the results. Finally, as this
is a cross-sectional study, we did not have serial blood tests, and we cannot rule out the risk of reverse
causation, for example, that low neonatal IL-6 levels are the cause of higher neonatal WB-Iron content,
which could be caused by lower hepcidin levels.
4.3. Future Perspective
During the fetal period and the first years of life, there is rapid development in the immune
system. Excessive iron levels have been linked to T1D in both childhood and in adulthood [11,12];
whether these associations are due to early-life adverse immunological changes still remains uncertain.
Interestingly, single nucleotide polymorphisms influencing iron status seems to be strongly associated
with DNA methylation [49], which may influence immunological pathways [50], and such effects
are believed to be long-lasting and not transient. Studies looking at the role of total tissue and
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circulating iron and immunological health would benefit from a triangulation strategy involving
causal epidemiology (Mendelian randomization (MR)), in vitro, and in vivo studies [51]. An MR
approach could examine if iron-related single nucleotide polymorphisms [52] were associated with
early life immunological alterations, for example, IL-6 and MBL. Further, associated genes could then
be knocked out or over-expressed in humanized murine models, and the immunological status could
then be examined in infant mice. Different in vitro cell lines could also be exposed to different iron
concentrations, for example, IL-6 producing monocytes or hepatocytes, and inflammatory signals, iron
chelators, and anti-IL-6-antibodies should also be used in combinations to delineate different effects of
iron on IL-6 production.
5. Conclusions
In summary, we found that higher neonatal WB-iron content was inversely associated with
IL-6 and MBL, which may increase susceptibility to infections.
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